[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020007293A - Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. - Google Patents

Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.

Info

Publication number
MX2020007293A
MX2020007293A MX2020007293A MX2020007293A MX2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A
Authority
MX
Mexico
Prior art keywords
methods
compositions
deuterated compounds
treating cancers
etbr
Prior art date
Application number
MX2020007293A
Other languages
English (en)
Inventor
Sumayah Jamal
Original Assignee
Enb Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enb Therapeutics Inc filed Critical Enb Therapeutics Inc
Publication of MX2020007293A publication Critical patent/MX2020007293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Aquí se describen compuestos deuterados, composiciones farmacéuticas de los mismos y métodos para tratar cánceres relacionados con ETBR. También se describe en el presente documento un sistema de administración para la liberación controlada y sistémica de al menos un antagonista de ETBR deuterado, opcionalmente junto con un agente anti oncológico adicional.
MX2020007293A 2018-01-12 2019-01-11 Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. MX2020007293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616729P 2018-01-12 2018-01-12
PCT/US2019/013377 WO2019140324A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Publications (1)

Publication Number Publication Date
MX2020007293A true MX2020007293A (es) 2021-01-08

Family

ID=67212721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007293A MX2020007293A (es) 2018-01-12 2019-01-11 Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.

Country Status (9)

Country Link
US (4) US10435434B2 (es)
EP (1) EP3713571A4 (es)
JP (1) JP7539151B2 (es)
KR (1) KR20200119246A (es)
CN (1) CN111886010A (es)
CA (1) CA3087009A1 (es)
EA (1) EA202091630A1 (es)
MX (1) MX2020007293A (es)
WO (1) WO2019140324A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018001507A (es) 2015-08-03 2018-09-18 Enb Therapeutics Llc Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
CN111886010A (zh) * 2018-01-12 2020-11-03 Enb治疗公司 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
WO2024092239A1 (en) * 2022-10-28 2024-05-02 Enb Therapeutics, Inc. Methods for treating cancers associated with etbr activation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
US5496928A (en) 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
TW217417B (es) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
AU2003286647B2 (en) 2002-10-24 2009-11-05 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US8257918B2 (en) 2004-07-07 2012-09-04 The Regents Of The University Of California Intelligent nanomedicine integrating diagnosis and therapy
US20080102451A1 (en) 2006-10-31 2008-05-01 Abbott Laboratories Companion diagnostic assays for endothelin receptor antagonists
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9289426B2 (en) 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
CN105055300A (zh) 2007-06-11 2015-11-18 R·骆克·麦克唐纳 用于预防脑血管痉挛的药物递送系统
US20110311525A1 (en) 2008-08-29 2011-12-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011019630A2 (en) 2009-08-10 2011-02-17 Board Of Regents, The University Of Texas System Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
US20140341916A1 (en) 2011-10-28 2014-11-20 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
JP6152391B2 (ja) 2012-03-02 2017-06-21 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント セラノスティクスにおいて有用なポリマーナノ粒子
WO2014025837A1 (en) 2012-08-06 2014-02-13 Board Of Regents, The University Of Texas System Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
MX2016007887A (es) 2013-12-17 2016-10-28 Genentech Inc Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
WO2015110593A1 (en) 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
AU2016262074A1 (en) 2015-05-12 2017-11-09 Genentech, Inc. Therapeutic and diagnostic methods for cancer
ES2810700T3 (es) 2015-05-29 2021-03-09 Hoffmann La Roche Metilación del promotor de PD-L1 en cáncer
IL294138A (en) 2015-05-29 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer
MX2018001507A (es) * 2015-08-03 2018-09-18 Enb Therapeutics Llc Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2017165491A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
CN111886010A (zh) 2018-01-12 2020-11-03 Enb治疗公司 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法
EP3746110A4 (en) 2018-03-30 2022-03-02 ENB Therapeutics, Inc. ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
CA3147639A1 (en) 2019-07-17 2021-01-21 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
US20200289495A1 (en) 2020-03-24 2020-09-17 Enb Therapeutics, Inc. Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) 2020-03-24 2020-08-27 Enb Therapeutics, Inc. Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer

Also Published As

Publication number Publication date
US20190345197A1 (en) 2019-11-14
WO2019140324A1 (en) 2019-07-18
US10435434B2 (en) 2019-10-08
AU2019206652A1 (en) 2020-07-16
CA3087009A1 (en) 2019-07-18
EP3713571A4 (en) 2021-08-25
JP7539151B2 (ja) 2024-08-23
KR20200119246A (ko) 2020-10-19
US12077604B2 (en) 2024-09-03
JP2021510680A (ja) 2021-04-30
US11066442B2 (en) 2021-07-20
EP3713571A1 (en) 2020-09-30
US20240360173A1 (en) 2024-10-31
US20190218251A1 (en) 2019-07-18
EA202091630A1 (ru) 2020-12-04
US20210309694A1 (en) 2021-10-07
CN111886010A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
ZA201902053B (en) Pharmaceutical composition
MX2016008362A (es) Combinaciones farmaceuticas.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
ZA201902051B (en) Pharmaceutical composition
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
IN2014MU00303A (es)
ZA201902049B (en) Pharmaceutical composition
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
EP3679608A4 (en) TRIPLET-TRIPLET ANNIHILATION CONVERSION-ELEVATION SYSTEM, AND ASSOCIATED COMPOSITIONS AND METHODS FOR DRUG DELIVERY
MX2021012029A (es) Composicion farmaceutica de corticosteroide soluble.
NZ733451A (en) Combination therapy for pulmonary hypertension
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer